AVAI Bio 10-K Flags Going Concern Doubt, $1.75M Loss, and Material Weaknesses
AVAI sits 52% above its 52-week low of $0.11.
Summary
AVAI Bio's 10-K reveals a going concern warning, a $1.75M net loss, no revenue, and only $23K in cash. Material weaknesses persist, and the company depends on dilutive debt and insider loans to survive.
Key Events · Earnings and Guidance · AVAI
-
Going Concern Warning
The independent auditor expresses substantial doubt about the company's ability to continue as a going concern, citing recurring losses, no revenue, and a stockholders' deficit of $2.8M.
-
Financial Deterioration
The net loss widened to $1.75M from $1.14M, while cash fell to $23,145. The working capital deficit increased to $3.3M, and no revenue was generated in FY2026.
-
Material Weaknesses
Disclosure controls and internal control over financial reporting remain ineffective due to a lack of an audit committee, poor cash controls, and inadequate IT controls.
-
Toxic Financing & Dilution
The company relies on high-interest convertible notes (22% default rate) and insider loans. Over 15M shares were issued in FY2026 to settle debts, with more notes issued post-year-end.
Analysis · AVAI · Technology
The annual report confirms severe financial distress. An auditor's going concern warning points to recurring losses and zero revenue, while cash stands at just $23,145 against $3.4M in current liabilities. Material weaknesses in internal controls remain unaddressed. To stay afloat, the company relies on toxic convertible debt and insider loans, issuing shares to settle obligations. The recent dissolution of the Ai-Nova joint venture removes a potential growth catalyst, materially increasing the risk of insolvency or highly dilutive financing.
At the time of this filing, AVAI was trading at $0.17 on OTC in the Technology sector, with a market capitalization of approximately $23.2M. The 52-week trading range was $0.11 to $0.80. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.